ELDN

Eledon Pharmaceuticals (ELDN)

About Eledon Pharmaceuticals (ELDN)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Details

Daily high

$3.16

Daily low

$2.84

Price at open

$3.11

52 Week High

$4.60

52 Week Low

$1.35

Market cap

232.8M

Dividend yield

0.00%

Volume

1.4M

Avg. volume

1.6M

P/E ratio

-5.22

Eledon Pharmaceuticals News